C Chevreau
Overview
Explore the profile of C Chevreau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
2230
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Honore C, Delhorme J, Nassif E, Faron M, Ferron G, Bompas E, et al.
Surg Oncol
. 2019 Jun;
29:107-112.
PMID: 31196472
Background: Despite being associated with a very poor prognosis, long-term survivors across all series of Desmoplastic Small Round Cell Tumor (DSRCT) have been reported. Aim Of The Study: To analyze...
12.
Blay J, Honore C, Stoeckle E, Meeus P, Jafari M, Gouin F, et al.
Ann Oncol
. 2019 Jun;
30(8):1407.
PMID: 31168580
No abstract available.
13.
Blay J, Honore C, Stoeckle E, Meeus P, Jafari M, Gouin F, et al.
Ann Oncol
. 2019 May;
30(7):1143-1153.
PMID: 31081028
Background: NETSARC (netsarc.org) is a network of 26 sarcoma reference centers with specialized multidisciplinary tumor boards (MDTB) aiming to improve the outcome of sarcoma patients. Since 2010, presentation to an...
14.
Mirjolet C, Merlin J, Truc G, Noel G, Thariat J, Domont J, et al.
EBioMedicine
. 2019 Mar;
41:420-426.
PMID: 30827931
Purpose: Radiation-induced sarcoma (RIS) is a rare but serious event. Its occurrence has been discussed during the implementation of new radiation techniques and justified appropriate radioprotection requirements. New approaches targeting...
15.
Boileve A, Carlo M, Barthelemy P, Oudard S, Borchiellini D, Voss M, et al.
J Immunother Cancer
. 2018 Dec;
6(1):159.
PMID: 30591082
Background: Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The prognosis in the metastatic (m) setting is poor. Programmed death ligand-1...
16.
Loriot Y, Pagliaro L, Flechon A, Mardiak J, Geoffrois L, Kerbrat P, et al.
Eur J Cancer
. 2017 Nov;
87:140-146.
PMID: 29149760
Background: The GETUG 13 phase III trial tested personalised chemotherapy based on tumour marker decline in patients with poor-prognosis germ-cell tumour (GCT) and demonstrated that a dose-dense regimen improves progression-free...
17.
Blay J, Soibinet P, Penel N, Bompas E, Duffaud F, Stoeckle E, et al.
Ann Oncol
. 2017 Nov;
28(11):2852-2859.
PMID: 29117335
Background: Sarcomas are rare but aggressive diseases. Specialized multidisciplinary management is not implemented for all patients in most countries. We investigated the impact of a multidisciplinary tumor board (MDTB) presentation...
18.
Salas S, Resseguier N, Blay J, Le Cesne A, Italiano A, Chevreau C, et al.
Ann Oncol
. 2017 Aug;
28(8):1979-1987.
PMID: 28838212
Background: Solitary fibrous tumors (SFT) are rare unusual ubiquitous soft tissue tumors that are presumed to be of fibroblastic differentiation. At present, the challenge is to establish accurate prognostic factors....
19.
Santos M, Brachet P, Chevreau C, Joly F
Cancer Treat Rev
. 2017 Jan;
53:53-60.
PMID: 28073101
Background: Molecular targeted therapies have improved progression-free survival (PFS) without translating systematically into overall survival (OS) for patients with metastatic renal cell carcinoma (mRCC). In this population, patient-reported outcomes (PROs)...
20.
Pouessel D, Neuzillet Y, Mertens L, van der Heijden M, de Jong J, Sanders J, et al.
Ann Oncol
. 2016 Apr;
27(7):1311-6.
PMID: 27091807
Background: Fibroblast growth factor receptor 3 (FGFR3) is an actionable target in bladder cancer. Preclinical studies show that anti-FGFR3 treatment slows down tumor growth, suggesting that this tyrosine kinase receptor...